Eugia Steriles Pvt Ltd receives 1st production approval from USFDA from new injectable facility

The new injectable facility of Eugia Steriles Private Limited (a 100% subsidiary of Eugia Pharma Specialities Limited and a stepdown subsidiary of AUROBINDO PHARMA LIMITED), situated at Parawada Mandal, Anakapalli District, Andhra Pradesh, which was inspected by the US FDA from March 28, 2024 to April 05, 2024, has now received its first product approval from the US FDA for Lidocaine Hydrochloride Injection, USP, 1% (10 mg/mL) and 2% (20 mg/mL). The sANDA was submitted as "Prior Approval Supplement" for addition of an alternate drug product manufacturing, labeling, packaging, and testing facility.

Shares of Aurobindo Pharma Limited was last trading in BSE at Rs. 1507.20 as compared to the previous close of Rs. 1518.45. The total number of shares traded during the day was 43928 in over 2693 trades.

The stock hit an intraday high of Rs. 1545.10 and intraday low of 1502.90. The net turnover during the day was Rs. 66894922.00.

Source : Equity Bulls

Keywords

AurobindoPharma INE406A01037 EugiaSteriles NewInjectableFacility USFDA FirstProductApproval LidocaineHydrochlorideInjection